Acquisition by Saenger Bradley of 540000 shares of Tonix Pharmaceuticals at 1.22 subject to Rule 16b-3

00182EBQ1   99.06  0.00  0.00%   
About 56% of ANZNZ's investor base is looking to short. The analysis of the overall prospects from investing in ANZNZ 5175122 18 FEB 25 suggests that many traders are, at the present time, alarmed. The current market sentiment, together with ANZNZ's historical and current headlines, can help investors time the market. In addition, many technical investors use ANZNZ 5175122 18 bond news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Tonix Pharmaceuticals Holding Officer Chief Financial Officer. Grant, award or other acquisition pursuant to Rule 16b-3

Read at macroaxis.com
Acquisition of 540000 stock option at 1.22 of Tonix Pharmaceuticals by Saenger Bradley on 5th of December 2024. This event was filed by Tonix Pharmaceuticals Holding with SEC on 2021-02-23. Statement of changes in beneficial ownership - SEC Form 4

ANZNZ 5175122 18 Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ANZNZ bond to make a market-neutral strategy. Peer analysis of ANZNZ could also be used in its relative valuation, which is a method of valuing ANZNZ by comparing valuation metrics with similar companies.

Peers

ANZNZ Related Equities

Other Information on Investing in ANZNZ Bond

ANZNZ financial ratios help investors to determine whether ANZNZ Bond is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ANZNZ with respect to the benefits of owning ANZNZ security.